The DOI matches its Crossref record; 316 of the 318 references it cites were found in a registry or an index, and 1 are not checked yet.
Combination strategies to maximize the benefits of cancer immunotherapy
Open accessAbstract
Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy (ACT) have revolutionized cancer treatment, especially in patients whose disease was otherwise considered incurable. However, primary and secondary resistance to single agent immunotherapy often results in treatment failure, and only a minority of patients experience long-term benefits. This review article will discuss the relationship between cancer immune response and mechanisms of resistance to immunotherapy. It will also provide a comprehensive review on the latest clinical status of combination therapies (e.g., immunotherapy with chemotherapy, radiation therapy and targeted therapy), and discuss combination therapies approved by the US Food and Drug Administration. It will provide an overview of therapies targeting cytokines and other soluble immunoregulatory factors, ACT, virotherapy, innate immune modifiers and cancer vaccines, as well as combination therapies that exploit alternative immune targets and other therapeutic modalities. Finally, this review will include the stimulating insights from the 2020 China Immuno-Oncology Workshop co-organized by the Chinese American Hematologist and Oncologist Network (CAHON), the China National Medical Product Administration (NMPA) and Tsinghua University School of Medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Accumulating evidence indicates that chemotherapy, radiotherapy, angiogenesis inhibitor, stimulator of interferon genes (STING) agonist, fecal microbiota transplantation (FMT), epigenetic modulators, or other immunomodulators could synergize α-PD-1/PD-L1, by enhancing cancer antigen release, APC function, or effector activity [22–31].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 1×
“Two coronavirus (COVID-19) mRNA vaccines approved in the US are both RNA vaccines formulated in lipid nanoparticles [285, 286].”
BackgroundEfficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · cited 1×
“Two coronavirus (COVID-19) mRNA vaccines approved in the US are both RNA vaccines formulated in lipid nanoparticles [285, 286].”
BackgroundCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · cited 1×
“Pembrolizumab + pemetrexed /platinum First‐line non‐squamous NSCLC May 10, 2017 [50, 296]”
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Research works printed but not linked: 1
- Shalabi H, Shah NN, Fry TJ, Yates B, Delbrook C, Yuan C, Stetler-Stevenson M, Ramakrishna S. Intensification of lymphodepletion optimizes CAR re-treatment efficacy. Blood. 2017;130(Supplement 1):3889–3889.
Cited by
Sorted by citations
Items 101–200 of 663
Guo, L., Chen, H. L., Ding, J., Rong, P., Sun, M., & Zhou, W. (2023) · Exploration · doi:10.1002/exp.20230017 · Cited by 38
Development of Platinum Complexes for Tumor Chemoimmunotherapy
Jin, S., Guo, Y., & Wang, X. (2024) · Chemistry - A European Journal · doi:10.1002/chem.202302948 · Cited by 37
The future of cancer treatment: combining radiotherapy with immunotherapy
Dagar, G., Gupta, A., Shankar, A., Chauhan, R., Macha, M. A., Bhat, A. A., Das, D., Goyal, R., Bhoriwal, S. K., PANDITA, R. K., et al. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1409300 · Cited by 36
Zhu, C., Li, H., Yang, X., Wang, S., Wang, Y., Zhang, N., Wang, Y., Xue, J., Zhang, L., Ning, C., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03466-8 · Cited by 36
The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC)
Wang, C.-W., Biswas, P. K., Islam, A., Chen, M., & Chueh, P. J. (2024) · Cells · doi:10.3390/cells13050413 · Cited by 35
Recent Developments in Nanoparticle‐Based Photo‐Immunotherapy for Cancer Treatment
Guo, Z., Zhu, A. T., Fang, R. H., & Zhang, L. (2023) · Small Methods · doi:10.1002/smtd.202300252 · Cited by 34
Tumor neoantigens: Novel strategies for application of cancer immunotherapy
Guan, H., Wu, Y., Li, L., Yang, Y., Qiu, S., Zhao, Z., Chu, X., He, J., Chen, Z., ZHANG, Y., et al. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.029924 · Cited by 34
Drug co-administration in the tumor immune microenvironment of Hepatocellular carcinoma
Shao, Y., Su, R., Wang, Y., Yin, S., Pu, W., Koo, S., & Yu, H. (2023) · Acupuncture and Herbal Medicine · doi:10.1097/hm9.0000000000000074 · Cited by 33
Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer
Xiao, F., Wang, Z., Liu, Q., Zhang, X., Wu, N., Wang, J., & Xing, Y. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05583-z · Cited by 32
A critical review of novel antibiotic resistance prevention approaches with a focus on postbiotics
Ozma, M. A., Moaddab, S. R., Hosseini, H., Khodadadi, E., Ghotaslou, R., Asgharzadeh, M., Abbasi, A., Kamounah, F. S., Maleki, L. A., Ganbarov, K., et al. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2214818 · Cited by 33
Therapeutic landscape of ovarian cancer: recent advances and emerging therapies
Wang, L., Zhang, Q., Wang, X., Dong, Z., Liu, S., Wang, Q., Zhang, Z., & Xing, J. (2025) · Biomarker Research · doi:10.1186/s40364-025-00818-7 · Cited by 32
Zheng, H., Wang, G., Liu, M., & Cheng, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1168226 · Cited by 32
Deng, G., Wang, P., Su, R., Sun, X., Wu, Z., Huang, Z., Gu, L., Yu, H., Zhao, Z., He, Y., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009983 · Cited by 32
Gynecological cancer tumor Microenvironment: Unveiling cellular complexity and therapeutic potential
Garg, P., Ramisetty, S. K., Subbalakshmi, A. R., Krishna, B. M., Pareek, S., Mohanty, A. R., Kulkarni, P., Horne, D. A., Salgia, R., & Singhal, S. S. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116498 · Cited by 30
Wang, J., Chen, Y., Xu, Y., Zhang, J., Yang, S., Zhou, Y. J., Lei, J., Ren, R., Chen, Y., Zhao, H., et al. (2024) · Theranostics · doi:10.7150/thno.102995 · Cited by 30
Grzybowski, M. M., Uçal, Y., Muchowicz, A., Rejczak, T. P., Kikulska, A., Głuchowska, K., Szostakowska-Rodzoś, M., Zagożdżon, A., Bausbacher, T., Tkaczyk, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-03446-1 · Cited by 30
Liu, W.-C., Wei, Y., Chen, J., Xing, X., Jia, H., Yang, X., Huang, Y., Liu, X.-M., Xiao, K., Guo, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60293-4 · Cited by 30
Xu, Y., Nowsheen, S., & Deng, M. (2023) · Cancers · doi:10.3390/cancers15051619 · Cited by 31
Ellingsen, E. B., O'Day, S. J., Mezheyeuski, A., Gromadka, A., Clancy, T., Kristedja, T. S., Milhem, M. M., & Zakharia, Y. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0416 · Cited by 30
Circulating tumor DNA methylation: a promising clinical tool for cancer diagnosis and management
Wang, B., Wang, M., Lin, Y., Zhao, J., Gu, H., & Li, X. (2024) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-1327 · Cited by 29
ROS-triggered nanoinducer based on dermatan sulfate enhances immunogenic cell death in melanoma
Zhang, Q., Li, S., Ren, J., He, X., Shi, H., Zhang, F., Li, H., & Tong, R. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.026 · Cited by 29
Advances in the study of CD47 ‐based bispecific antibody in cancer immunotherapy
Zhang, B., Li, W., Fan, D., Tian, W., Zhou, J., Ji, Z., & Song, Y. (2022) · Immunology · doi:10.1111/imm.13498 · Cited by 29
Ma, S., Zhu, J. W., Wang, M., Zhu, J., Wang, W., Xiong, Y., Jiang, R., Seetharamu, N., Abrão, F. C., Moorthi, P. V., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-660 · Cited by 29
Cheng, K., Feng, X., Chai, Z., Wang, Z., Liu, Z., Yan, Z., Wang, Y., & Zhang, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044197 · Cited by 29
Yin, Y., Yan, Y., Fan, B., Huang, W., Zhang, J., Hu, H., Li, X., Xiong, D., Chou, S., Xiao, Y., et al. (2023) · Research · doi:10.34133/research.0098 · Cited by 29
Nanozymes in cancer immunotherapy: metabolic disruption and therapeutic synergy
Xu, X., Zhang, Y., Meng, C., Zheng, W., Wang, L., Zhao, C., & Luo, F. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00769g · Cited by 28
Jia, D., Cai, J., Zhong, Y., Wang, C., Huang, S., Zeng, Y., Fan, Z., Xu, C., Hu, L., Zhang, J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101229 · Cited by 27
Abouzeid, H. A., Kassem, L. M. H., Liu, X., & Abuelhana, A. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100918 · Cited by 27
Li, R., Hao, Y., Roche, K. C., Chen, G., Pan, W., Wang, A. Z., & Min, Y. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122290 · Cited by 27
Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance
Yao, L., Wang, Q., & Ma, W. (2023) · Cancers · doi:10.3390/cancers15245857 · Cited by 27
IL-24 improves efficacy of CAR-T cell therapy by targeting stemness of tumor cells
Zhang, K., Hu, W., Li, F., Wen, C., Zhou, L., Zhang, L., Lian, J., Liu, S., Wang, S., & Zhang, Y. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02601-1 · Cited by 27
Zhao, G., Wang, S., Nie, G., & Li, N. (2024) · Med · doi:10.1016/j.medj.2024.03.012 · Cited by 27
Leveraging Artificial Intelligence for Neoantigen Prediction
Zeng, J., Lin, Z., Zhang, X., Zheng, T., Xu, H., & Liu, T. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-2553 · Cited by 26
Xu, K., Gu, T., Su, K., Liu, X., He, B., He, J., Chi, H., Zhou, X., Liu, H., Xiao, R., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02914-4 · Cited by 26
Self-citationKhan, M. S., Rehman, U., Alqahtani, T., Shmrany, H. A., Gupta, G., Goh, K. W., Sahebkar, A., & Kesharwani, P. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02435-2 · Cited by 26
Role of epigenetics in OSCC: an understanding above genetics
Vatsa, P. P., Jindal, Y., Bhadwalkar, J., Chamoli, A., Upadhyay, V., & Mandoli, A. (2023) · Medical Oncology · doi:10.1007/s12032-023-01992-0 · Cited by 26
Lee, K.-J., Choi, D., Tae, N., Song, H. W., Kang, Y., Lee, M., Moon, D., Oh, Y., Park, S., Kim, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101567 · Cited by 26
Hashemi, M., Khosroshahi, E. M., Tanha, M., Khoushab, S., Bizhanpour, A., Azizi, F., Mohammadzadeh, M., Matinahmadi, A., Koohpar, Z. K., Asadi, S., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37376 · Cited by 25
Zhang, X., Tian, H., Chen, Y., Liang, B., Nice, E. C., Huang, C., Xie, N., & Zheng, S. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02836-3 · Cited by 25
Wang, Y., Jiang, C., Zhou, H., & Han, R. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00705-9 · Cited by 25
Wu, S., Bai, H., Zhang, L., He, J., Luo, X., Wang, S., Fan, G., & Sun, N. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.969942 · Cited by 25
Yan, W., Lang, T., Yuan, W., Yin, Q., & Li, Y. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00976-6 · Cited by 25
Understanding the landscape of immunotherapy in thymic epithelial tumors
Maniar, R., & Loehrer, P. J. (2023) · Cancer · doi:10.1002/cncr.34678 · Cited by 25
Cell Therapy as Target Therapy against Colon Cancer Stem Cells
Garza Treviño, E. N., Quiroz Reyes, A. G., Rojas Murillo, J. A., de la Garza Kalife, D. A., Delgado Gonzalez, P., Islas, J. F., Estrada Rodriguez, A. E., & Gonzalez Villarreal, C. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098163 · Cited by 24
Bi, Y., Chen, J., Li, Q., Li, Y., Zhang, L., Zhida, L., Yuan, F., & Zhang, R. (2024) · iScience · doi:10.1016/j.isci.2024.108833 · Cited by 24
Rached, L., Peyre-Pradat, F., Spotti, M., Baldini, C., Laparra, A., Lambotte, O., Sakkal, M., Perret, A., Viansone, A. A., Michiels, S., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100061 · Cited by 24
Luo, Y., Linghu, M., Luo, X., Li, D., Wang, J., Peng, S., & Ma, Y. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.12.014 · Cited by 24
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization
Bertin, P., Rector-Brooks, J., Sharma, D. K., Gaudelet, T., Anighoro, A., Groß, T., Martínez‐Peña, F., Tang, E. L., Suraj, M. S., Regep, C., et al. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100599 · Cited by 25
A method for predicting drugs that can boost the efficacy of immune checkpoint blockade
Xia, Y., Li, X., Bie, N., Pan, W., Miao, Y., Yang, M., Gao, Y., Chen, C., Liu, H., Gan, L., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01789-x · Cited by 24
Self-citationMinaei, E., Ranson, M., Aghmesheh, M., Sluyter, R., & Vine, K. L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.023 · Cited by 24
Current Trends and Innovative Approaches in Cancer Immunotherapy
Kim, J.-C., Maharjan, R., & Park, J. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-02883-x · Cited by 25
Xu, Q., & Shao, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1487610 · Cited by 24
Desvaux, E., Aussy, A., Hubert, S., Keime-Guibert, F., Blesius, A., Soret, P., Guedj, M., Pers, J., Laigle, L., & Moingeon, P. E. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2012452 · Cited by 23
Lu, M., Xing, H., Shao, W., Wu, P., Fan, Y., He, H., Barth, S., Zheng, A., Liang, X., & Huang, Y. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.03.020 · Cited by 23
Zhang, Y., Zhang, Y., Li, Y., Fu, Y., Zhao, Y., Zhao, W. H., Li, C., Xian, Y., Tu, K., Wu, F., et al. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.145685 · Cited by 23
Lee, J., Kim, D., Kong, J., Ha, D., Kim, I., Park, M., Lee, K., Im, S., & Kim, S. (2024) · Science Advances · doi:10.1126/sciadv.adj0785 · Cited by 23
Enhanced cellular therapy: revolutionizing adoptive cellular therapy
Xu, M., Zeng, N., Liu, C., Sun, J., An, Y., Zhang, S.-H., Xu, J., Zhong, X., Ma, S., He, H., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00506-6 · Cited by 24
ACSL4-mediated lipid rafts prevent membrane rupture and inhibit immunogenic cell death in melanoma
Zhao, X., Zhao, Z., Li, B., Huan, S., Li, Z., Xie, J., & Liu, G. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07098-3 · Cited by 23
Self-citationRadiation therapy in the era of immune treatment for hepatocellular carcinoma
Chen, L., Zhang, R., Lin, Z., Tan, Q., Huang, Z., & Liang, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1100079 · Cited by 22
Immune checkpoint inhibitors as a threat to reproductive function: A systematic review
Tuerxun, H., Zhao, Y., Li, Y., Li, Y., Wen, S., Cao, J., Cao, J., & Zhao, Y. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104064 · Cited by 22
Development and Characterization of Novel FAP-Targeted Theranostic Pairs: A Bench-to-Bedside Study
Huang, W., Pang, Y., Liu, Q., Liang, C., An, S., Wu, Q., Zhang, Y., Huang, G., Chen, H., Liu, J., et al. (2023) · Research · doi:10.34133/research.0282 · Cited by 22
An AI-based approach for modeling the synergy between radiotherapy and immunotherapy
Peng, H., Moore, C., Zhang, Y., Saha, D., Jiang, S. B., & Timmerman, R. D. (2024) · Scientific Reports · doi:10.1038/s41598-024-58684-6 · Cited by 22
NK cell transfer overcomes resistance to PD-(L)1 therapy in aged mice
Hou, J., Xie, S., Gao, J., Jiang, T., Zhu, E., Yang, X., Jin, Z., Long, H., Zhang, A., Yang, F., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00511-9 · Cited by 22
Nanostructure-reinforced multifunctional hydrogels for synergistic cancer therapy
Yousefiasl, S., Ghovvati, M., Mirshafiei, M., Hakimi, F., Azadi, A., Moezzi, S. M. I., Yuan, M., Sefat, F., Zare, I., Maleki, A., et al. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216207 · Cited by 22
Mohamed, A. M., Abou‐Ghadir, O. F., Mostafa, Y. A., Almarhoon, Z. M., Braese, S., & Youssif, B. G. M. (2024) · RSC Advances · doi:10.1039/d4ra06694d · Cited by 22
Jiang, P., Fan, J., Zhang, C., Bai, M., Sun, Q., Chen, Q., Mao, W., Tang, B., Lan, H., Zhou, Y., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.84781 · Cited by 21
Roe, J. M., Seely, K. D., Bussard, C. J., Martin, E. E., Mouw, E. G., Bayles, K. W., Hollingsworth, M. A., Brooks, A. E., & Dailey, K. M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15072004 · Cited by 21
Targeting alternative splicing in cancer immunotherapy
Han, N., & Liu, Z. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1232146 · Cited by 21
Advancing non-small cell lung cancer treatment: the power of combination immunotherapies
Wu, Y., Yu, G., Jin, K., & Qian, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1349502 · Cited by 23
Clinical glycoproteomics: methods and diseases
Wang, Y., Lei, K., Zhao, L., & Zhang, Y. (2024) · MedComm · doi:10.1002/mco2.760 · Cited by 21
How the Versatile Self‐Assembly in Drug Delivery System to Afford Multimodal Cancer Therapy?
Cao, Y., Zhao, X., Miao, Y., Wang, X., & Deng, D. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202403715 · Cited by 20
Cho, Y. S., Kim, H. R., Park, S. J., Chung, S. W., Ko, Y. G., Yeo, J. H., Lee, J., Kim, S. K., Choi, J. U., Kim, S. Y., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121783 · Cited by 20
Li, Y., Jiang, X., Luo, T., Xia, J., Lee, M. J., Weichselbaum, R. R., & Lin, W. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121831 · Cited by 20
Cho, O., Lee, J.-W., Kim, H., Jeong, Y.-J., & Heo, T. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121559 · Cited by 20
Pizzutilo, E. G., Romanò, R., Roazzi, L., Agostara, A. G., Oresti, S., Zeppellini, A., Giannetta, L. G., Cerea, G., Signorelli, D., Siena, S., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0161 · Cited by 20
Exploring HERV-K (HML-2) Influence in Cancer and Prospects for Therapeutic Interventions
Costa, B., & Vale, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914631 · Cited by 20
Zhu, S., Liang, B., Zhou, Y., Chen, Y., Fu, J., Qiu, L., & Lin, J. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06480-1 · Cited by 20
Self-citationAyass, M. A., Tripathi, T., Griko, N., Okyay, T., Nair, R. R., Zhang, J., Zhu, K., Melendez, K., Pashkov, V., & Abi-Mosleh, L. (2024) · Cancers · doi:10.3390/cancers16051041 · Cited by 20
Emerging Targets and Therapeutics in Immuno-Oncology: Insights from Landscape Analysis
Iyer, K. A., Ivanov, J. M., Tenchov, R., Ralhan, K., Rodríguez, Y., Sasso, J. M., Scott, S. A., & Zhou, Q. A. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00568 · Cited by 20
Chimeric antigen receptor NK cells for breast cancer immunotherapy
Wu, N., Yang, N., Zhang, S., Wu, H., Fang, X., Lin, W., Zhang, Y., Qi, X., & Gong, Y. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102943 · Cited by 19
CAR Beyond αβ T Cells: Unleashing NK Cells, Macrophages, and γδ T Lymphocytes Against Solid Tumors
Xian, Y., & Wen, L. (2025) · Vaccines · doi:10.3390/vaccines13060654 · Cited by 19
Nazemiyeh, A., Dadashi, H., Mashinchian, M., Karimian-Shaddel, A., Mohabbat, A., Eskandani, M., & Vandghanooni, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-07996-2 · Cited by 19
Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases
Chen, X., Liu, K., Liu, B., Li, S., Wang, Y., Du, X., Weng, J., Song, B., Wu, K., & Lai, P. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01769-0 · Cited by 19
Hashemi, F., Razmi, M., Tajik, F., Zöller, M., Manshadi, M. D., Mahdavinezhad, F., Tiyuri, A., Ghods, R., & Madjd, Z. (2022) · Stem Cells · doi:10.1093/stmcls/sxac089 · Cited by 19
Zhang, T., Tian, W., Wei, S., Lu, X., An, J., He, S., Zhao, J., Gao, Z., Li, L., Lian, K., et al. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00426-x · Cited by 19
Self-citationNanomedicine Targeting Myeloid‐Derived Suppressor Cells Enhances Anti‐Tumor Immunity
Yang, E., & Sun, Z. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202303294 · Cited by 19
The significance of targeting lysosomes in cancer immunotherapy
Xu, Y., Shao, B., & Zhang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1308070 · Cited by 21
Patra, R., Halder, S., Saha, R., Jana, K., & Sarkar, K. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c00115 · Cited by 19
Liu, X., Zheng, H., Peng, Y., Ji, D., Wang, C., Wang, D., Jia, Z., Chang, Y., Cai, X., Wang, L., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01046 · Cited by 18
Effects of the Alkylating Agent Cyclophosphamide in Potentiating Anti-Tumor Immunity
Gephart, B. D., Coulter, D. W., & Solheim, J. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136440 · Cited by 18
Zheng, X., Lei, S., Yiwei, Z., Chen, L., Chen, J., Fu, W., Chen, Y., Hu, X., Wang, J., Jin, M., et al. (2025) · Advanced Materials · doi:10.1002/adma.202510936 · Cited by 18
Nanomedicines for high‑intensity focused ultrasound cancer treatment and theranostics (Review)
Zheng, Q., Xia, B., Huang, X., Luo, J., Zhong, S., & Li, X. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11869 · Cited by 18
Falcone, N., Ermis, M., Gangrade, A., Choroomi, A., Young, P., Mathes, T. G., Monirizad, M., Zehtabi, F., Mecwan, M. M., Rodriguez, M., et al. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202309069 · Cited by 18
A promising target for breast cancer: B7-H3
Jiang, Y., Liu, J., Chen, L., Qian, Z., & Zhang, Y. (2024) · BMC Cancer · doi:10.1186/s12885-024-11933-3 · Cited by 18
Current advances on the role of ferroptosis in tumor immune evasion
Gao, C., Zhang, H., & Wang, X. (2024) · Discover Oncology · doi:10.1007/s12672-024-01573-1 · Cited by 18
Permanently Charged Cationic Lipids—Evolution from Excipients to Therapeutic Lipids
Pushpa Ragini, S., Banerjee, R., Drummond, C. J., & Conn, C. E. (2024) · Small Science · doi:10.1002/smsc.202300270 · Cited by 17
Akter, Z., Salamat, N., Ali, M. Y., & Li, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1072739 · Cited by 17
Self-citationZhou, F., Li, X., Xue, X., Li, S., Fan, G., Cai, Y., Chang, Z., Qu, J., & Liu, R. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202757 · Cited by 17
Qiao, W., Hu, C., Ma, J., Dong, X., Dalangood, S., Li, H., Yuan, C., Lu, B., Gao, W., Wen, Z., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216370 · Cited by 17
Aggressive pituitary tumors and carcinomas: medical treatment beyond temozolomide
Alcubierre, D. D., Carretti, A. L., Ducray, F., Jouanneau, E., Raverot, G., & Ilie, M. D. (2024) · Minerva Endocrinology · doi:10.23736/s2724-6507.23.04058-7 · Cited by 17
Metadata
- Authors
- Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X.
- Affiliations
- Beijing Chao-Yang Hospital, Capital Medical University (CN)
- Duke University (US)
- Johns Hopkins University (US)
- University of Chicago (US)
- New York Medical College (US)
- The Ohio State University (US)
- Harvard University (US)
- Corresponding author
- Li, Zihai
- Pan, Chong-xian
- Venue
- Journal of Hematology & Oncology
- Published
- 2021-09-27
- Volume
- 14
- Issue
- 1
- Pages
- 156-156
- ISSN
- 1756-8722 (ISSN-L)
- PMC
- PMC8475356
- OpenAlex
- W3202901824
- Cited by
- 654
- References
- 318
- Citations by year
- 2026: 78 · 2025: 163 · 2024: 206 · 2023: 127 · 2022: 77 · 2021: 2
- FWCI
- 12.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Hematology & Oncology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Touro Scholar (Touro College) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Tsinghua University
- National Cancer Institute (P50CA062924)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cancer immunotherapy, combination therapy, immune checkpoint blockade, adoptive immunotherapy, immunotherapy resistance, cancer vaccines, virotherapy, cytokine-targeted therapy, combination chemotherapy, radiation therapy combination, combination targeted therapy
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Combined Modality Therapy, Humans, Immunotherapy, Neoplasms, Cancer Vaccines, Oncolytic Virotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
